IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

		RECEIVED CENTRAL FAX CENTER
Applicant(s):	Matthew Baker et al.	APR 1 1 2007
Application No.	10/560,918	
Filed:	December 16, 2005) Group Art Unit: 1656
For:	MODIFIED HIRUDIN PROTEINS AND T-CELL EPITOPES IN HIRUDIN	
Examiner:	Karen C. Carlson) Attorney Docket No. <u>MER-142</u>

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This communication is submitted in response to the Office Action dated 27 March 2007 on the above-identified application. In response thereto, applicants hereby elect the peptide represented by SEQ ID NO: 1 for further prosecution at this time. Claim 9 defines the elected invention.

Early passing of this application to issue is solicited.

Respectfully submitted,

April 11, 2007

Talivaldis Cepuritis (Reg. 70. 20,818)

OLSON & HIERL, LTD. 20 North Wacker Drive, 36th Floor Chicago, Illinois 60606 (312) 580-1180

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this RESPONSE TO RESTRICTION REQUIREMENT is being transmitted by facsimile transmission to Fax No. 571-273-8300 on April 11, 2007.

Talivaldis Cepuritis (Reg. No/20,818)